We present our experience with three clinical scale isolation methods for positive selection of CD34 + progenitors from peripheral blood for autologous and allogeneic transplantation in children. A combination of the CellPro device and the Magnetic Activated Cell Sorting system (MACS), as well as two different combinations of MACS systems were used (VarioMACS-SuperMACS and SuperMACS-SuperMACS). With the CellPro-MACS combination (16 separations), a median purity of 96.2% and a median recovery of 42% CD34 + cells could be achieved, whereas the two step MACS systems (55 and 29 separations) showed a median purity of 97.6% and 98.0% and a median recovery of 96.5% and 97%, respectively. Depletion of T cells was profound (4-5 log). A total of 34 patients in the autologous and 18 patients in the allogeneic setting have been transplanted with highly enriched CD34 + cells, obtained by these methods. Only one patient failed to engraft, all other patients showed a rapid and sustained hematological engraftment with the longest follow-up of 3 years. In summary, especially the two step MACS systems have proven to be appropriate tools for enrichment of CD34 + cells, yielding both high purity and good recovery, and can thus be used for tumor cell purging in the autologous setting and for effective T cell depletion in the allogeneic setting.
can be achieved by enrichment of CD34 + progenitors and indirect depletion of all other cell types.
Our aim was to establish a method for clinical use in pediatric disorders which yields a maximum purity of CD34 + progenitors in combination with acceptable recoveries. A well known procedure is the CellPro CEPR-ATE SC device which has been used in a variety of clinical settings. [1] [2] [3] 9 However, this system might be less effective especially in patients with low numbers of CD34
+ cells prior to the separation. 5 A recently described laboratory scale method is magnetic activated cell sorting (MACS), which yields high purities and recoveries. [10] [11] [12] Cells are labeled with very small superparamagnetic microbeads (50 nm in size), followed by separation on various sized high gradient magnetic separation columns, employing a small Varioor large SuperMACS system. We have recently demonstrated that the large scale version (SuperMACS) can also be used for positive selection of autologous peripheral CD34 + progenitors in the clinical setting. 13 This has also been reported by DiNicola et al. 12 In this paper, we present our experience in 3 years of enrichment of CD34 + cells for autologous and allogeneic transplantation with three clinical scale separation procedures: a combination of the Ceprate SC device and VarioMACS system, and the two step MACS systems (VarioMACS and SuperMACS or SuperMACS and SuperMACS).
Patients and methods

Autologous CD34
+ progenitors were isolated from 43 pediatric patients suffering from solid tumors (neuroblastoma, lymphoma). Age and body weight ranged from 2 to 16 years (median 4 years) and from 8 to 80 kg, respectively (median 16 kg). Separations were also carried out in two adult patients (lymphangiosarcoma, lymphoma). Allogeneic CD34
+ cells were isolated for 23 patients, suffering from acute leukemias (n = 10), myelodysplastic syndromes (n = 4), chronic myeloid leukemias (n = 2), severe aplastic anemia (n = 2), thalassemia (n = 1), severe combined immunodeficiency (n = 2), Wiskott-Aldrich (n = 1) and osteopetrosis (n = 1). Age and body weight ranged from 0.5 to 23 years (median 10 years) and 5 to 73 kg, respectively (median 30 kg). Healthy haploidentical, 1-3 loci mismatched family donors (parents, n = 16) and matched related (n = 2) or matched nonrelated donors (n = 5) were used (Table 1) . 
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Peripheral stem cell collection and mobilization
The mobilization of autologous hematopoetic progenitor cells from bone marrow into peripheral blood was initiated by a cytostatic regimen in accordance with the therapeutic protocol of each patient followed by G-CSF s.c.
(10 g/kg/day). Leukaphereses were carried out via Hickman catheter and a peripheral venous access and started during the hematopoetic recovery phase at a WBC Ͼ10 × 10 9 /l using a Fenwall CS3000 cell separator (Baxter, Munich, Germany) as described previously. 13 In the allogeneic setting, normal healthy donors were mobilized with G-CSF s.c. (10 g/kg/day) for 5 days followed by one to two large volume leukaphereses, using peripheral venous accesses.
CD34
+ selection
Three cell separation procedures were used: a combination of the Ceprate SC stem cell concentrator (CellPro, Bothell, WA, USA) and the VarioMACS (VMACS) device, or two step MACS systems, consisting of the SuperMACS (SMACS, large scale system) for the first step, followed by either the VarioMACS device (laboratory scale system, both Miltenyi Biotec, Bergisch Gladbach, Germany) or another round of SMACS for the second step. The separation with Ceprate SC was carried out following the procedure recommended by the manufacturer with some modifications. Briefly, platelets were reduced by washing steps at 450 g, 5 min with the Cobe cell processor (Cobe Laboratories, Lakewood, CO, USA). Cells were then incubated with biotinylated anti-CD34 antibody in PBS/0.1% HSA for 20 min followed by a wash with 1000 ml PBS to remove unbound antibody, before passing through the column. Bound CD34 + cells were removed from the column by gentle agitation and additionally by eluating with 50 ml PBS.
The MACS separation technique was carried out as follows: cells were treated with 200 units/ml DNAse (Bohringer Mannheim, Mannheim, Germany) at room temperature for 30 min followed by a Ficoll separation (500 g, 30 min) if the total erythrocyte number exceeded 6 × 10 10 cells. The cells were then washed twice and resuspended at a concentration of 3 × 10 8 cells/ml in pre-chilled separation buffer (PBS − /0.5% HSA/5 mm EDTA). 100 l blocking reagent per 10 8 cells was added with a 5 min incubation at 4°C, followed by a further incubation with the antibody solution (Miltenyi, (Miltenyi) were used, an antibody staining step was not recommended. Cells were washed once, resuspended in degassed separation buffer and filtered through a 50 m nylon mesh. Care was taken to adhere to a maximal concentration of 2 × 10 8 cells/ml. Cells were then passed through a SMACS XS + column (Miltenyi) once at a rate of 300 ml/h. The column was washed with 3 × 50 ml separation buffer at a rate of 400 ml/h. Then the column was removed from the magnetic field and remaining cells were manually eluted with 2 × 25 ml degassed buffer at maximum speed. For the second separation step, either the VMACS device with VS + columns (Miltenyi) or another round of the SMACS system was used. A maximum of 1 × 10 8 expected CD34 + cells was passed through one VMACS VS + column. Unbound cells were washed out with 5 × 2 ml pre-chilled degassed separation buffer. After removing the column from the magnetic field, the remaining cells were eluted with 8 ml separation buffer. Some modifications were made with the second SMACS step: cells were run through another XS + column. Remaining cells were then eluted and allowed to pass through the same column a second time, followed by two additional wash steps with separation buffer using an enhanced rate of 500 ml/h. When the MACS system was used as a second separation step following the CellPro device, no Ficoll-Hypaque gradient centrifugation was necessary. Cells were treated with DNase for 15 min at 4°C. Blocking reagent, antibody solution and magnetic particles were added in variable amounts depending on the percentage of CD34 + cells after CellPro enrichment (Ͼ10% CD34 + : 200 l/10 8 cells, Ͼ50% CD34 + : 300 l/10 8 cells).
Hematopoietic progenitor assay
Mononuclear cells were plated at 1 × 10 5 cells/ml for the unseparated PBSC and 1 × 10 3 /ml for the CD34 + enriched fraction in methylcellulose supplemented with PHA conditioned medium (Terry Fox, Vancouver, Canada). Aggregates of 40 or more cells after 14 days incubation were scored as CFU-C. The recovery of CFU-C was defined as total number of CFU-C in the initial fraction/total number of CFU-C cells in the enriched fraction ×100. Recovery values Ͼ100% were set for statistical calculation as 100.
Colony-forming efficacy (CFE) was calculated as number of colonies/number of viable CD34 + cells seeded.
Flow cytometry
Cell populations before and after separation were stained with anti-CD34-PE (HPCA-2), anti-CD3-FITC, anti-CD19-PE and nonbinding isotype IgG, as controls (BectonDickinson, Heidelberg, Germany). FACS analysis was performed on FACScan or FACSCalibur instruments (BectonDickinson). Debris, dead cells, cell aggregates and platelets were excluded by gating on forward scatter and sideward scatter. A minimum of 10 000 events (50 000 in the last set of separations) was used for assessment. For CD34 + enumeration, gated cells were analyzed with dot plot diagrams (fluorescense II vs side light scatter) according to the Milan/Mulhouse protocol, 14 as shown in Figure 1 . In most separations, a clear CD34
+ population was seen in the initial sample. In some cases however, the number of cells in the CD34
+ initial population was too low for accurate determination.
The Procount kit and software (Becton-Dickinson) was additionally used in 30 separations for enumeration of CD34 + cells in apheresis products, according to the manufacturer's instructions. The total number of CD34
+ cells before and after the separation was calculated by multiplying the percentage of CD34
+ cells by the total number of cells and dividing by 100.
The recovery of CD34 + cells was defined as total number of CD34
+ cells in the initial fraction/total number of CD34 + cells in the enriched fraction ×100. Recovery numbers Ͼ100% were set for statistical calculation as 100.
Statistical analysis
The normality of distribution was assessed and, in the case of non-normality, statistical analysis was performed by using the nonparametric Wilcoxon rank sum test. 
Results
One hundred separations in 66 patients were performed. In 43 patients suffering from solid tumors, autologous, peripheral CD34 + progenitors were collected as stem cell rescue after high-dose chemotherapy, with the aim of removing contaminating tumor cells indirectly by enrichment of CD34 + progenitors. In 23 patients allogeneic CD34
+ progenitors from one to three loci mismatched family donors or matched related and unrelated donors were isolated. In this case the purpose was to deplete T cells.
Processed cell numbers are listed in Table 1 .
Enrichment with CellPro and VMACS
With this combination, 16 separation procedures were carried out. The recovery and purity of CD34 + cells and CFU-C are shown in Table 2 . Median purity after separation was 96.2% (range 83.9-99.2%, mean 95.2 Ϯ 3.6%). In 15 separations, the purity exceeded 90%. The median frequency of CD34
+ cells in the initial sample was 0.4% (range from 0.2-4.8%, mean 0.9 Ϯ 1.2%). The median recovery of CD34 + cells was 42% (mean 46%). The median recovery of CFU-C was 62% (mean 57%). In three separations, the recovery numbers exceeded 100%. FACS analysis of cells revealed a median percentage of 0.2% T cells (range from Ͻ0.01-1.1%, mean 0.3 Ϯ 0.3%) and 0.6% B cells (range 0.1-5.5%, mean 1.4 Ϯ 1.6%), corresponding to a median number of 0.8 × 10 4 T cells/kg body weight per separation and to a median T cell depletion of about 4 log ( Table 3) .
Enrichment with the two step MACS systems SMACS and VMACS:
With this combination 55 separations were performed. Purities and recoveries are shown in Table 2 . A distinct population of lymphocytes was generally observed with FACS analysis. In separations with lower purities, contamination was typically caused by monocytes. The median percentage of CD34 + in the initial fraction was 0.4% (mean 1.0 Ϯ 1.4%) and ranged from 0.01% to 6.9%. Median purity after separation was 97.6% (range 33.4-99.3%, mean 93.0 Ϯ 12.7%). In 46 (ie 84%) separations the purity exceeded 90%. In only four separations (7%) was the purity below 80% (Figure 2 ). In two separations, an extremely low number of starting CD34
+ cells (0.01 and 0.04%, total cell number 0.5 and 1.6 × 10 6 according to the Procount analysis) resulted in purities below 60% in the enriched fraction. The median recovery of CD34 + was 96.5% (mean 84 Ϯ 20%). Recovery exceeded 100% in 23 separations. This means that the CD34 + starting population could not be enumerated correctly by FACS analysis. Thus, recoveries greater than 100% were set for statistical calculation as 100. In 30 separations, the Procount system was used additionally for enumeration of CD34 + cells. A median recovery of 87.0% (mean 85.0 Ϯ 14.8%) was calculated with this method. No significant difference between the enumeration methods could be seen (data not shown). The median recovery of CFU-C was 53.5% (mean 59 Ϯ 32%). In 15 separations,
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SMACS and SMACS:
Twenty-nine separations were carried out with this procedure ( Table 2 ). The median frequency of CD34
+ in the initial sample was 0.4% (range 0.02-5.9%, mean 0.7 Ϯ 1.1%).The median purity after separation resulted in 98.0% (range 51.1-99.6%, mean 94.1 Ϯ 10.6%). In 86% of separations, the purity was Ͼ90%. Only three separations (10%) showed inferior results below 80% due to contamination with monocytes and very low number of starting CD34
+ . The median recovery of CD34 + was 97% (mean 84 Ϯ 20%). In 12 separations, recovery number exceeded 100%. A median recovery of CFU-C of 88% (mean 64 Ϯ 42%) was achieved. A median percentage of 0.05% T cells (Ͻ0.01-0.97%, mean
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+ progenitors P Lang et al 587 0.12 Ϯ 0.19%) and 1.6% B cells (0.25-12.6%, mean 2.6 Ϯ 3%) were still detected after separation, corresponding to a median number of 0.3 × 10 4 T cells/kg body weight and to a median T cell depletion of about 5 log (Table 3) .
Viability
Viability of enriched CD34
+ cells as determined by Trypan blue staining was over 90% in all separation systems.
Clinical results
A total of 34 patients in the autologous and 18 patients in the allogeneic setting have been transplanted with highly enriched progenitors obtained by these methods. Only one patient with severe aplastic anemia failed to engraft. All other patients showed a rapid and complete hematopoietic engraftment. Patients in the autologous setting received a median number of 3.7 × 10 6 CD34 + stem cells/kg with a median time of 12 days to reach 500 neutrophils/l. T cells (including CD4
+ helper cells), B cells and NK cells reached low normal values within 2 months after transplantation and were completely normalized after 8 months. In the allogeneic setting, a median number of 18 × 10 6 CD34 + cells/kg was achieved. Median time to reach 500 neutrophils/l was 11 days. Due to the profound depletion of T cells (median 1.5 × 10 4 T cells/kg body weight), no significant GVHD (ϾI) occurred, even when haploidentical, three loci mismatched donors were chosen. Median time to reach 300/l CD3 + cells was 80 days. Due to this rapid immunoreconstitution, only one lethal infection was observed.
Discussion
Our aim was to establish a clinical scale procedure, that offers both a maximum purity and an acceptable recovery of CD34 + progenitors. In this paper, our experience with three separation procedures is presented: a combination of the Ceprate SC device and the VMACS and two different two step MACS systems (SMACS and VMACS or SMACS and SMACS).
We have demonstrated, that pre-enrichment with the CellPro method followed by a second separation step with the VMACS is a suitable combination, providing a very high purity of CD34 + cells. Although two different CD34 antibodies were required, no negative impact could be seen. It should be noted however, that the CellPro system is no longer available for this purpose. In our hands a mean purity of 30% could be achieved with the Ceprate SC. This percentage is low when compared with results obtained by others. [2] [3] [4] This may be because the separation regimen recommended by the manufacturer was modified for a higher recovery (columns were additionally eluted several times). With the SMACS-VMACS combination, purities of over 95% were regularly obtained in 74% of separations (Figure 2) . Extremely low starting CD34 + numbers (Ͻ0.05%) impaired the purity, probably due to nonspecific binding of cells in the column. Contaminating cells were monocytes with some granulocytes. Only very low numbers of T and B cells were detected. Other separations showed sufficient CD34
+ starting numbers but with distinct populations of monocytes in the enriched fraction. This may have been due to phagocytosis of beads by these cells.
Results obtained by the SMACS-SMACS combination were very similar to the SMACS-VMACS procedure. No significant difference could be seen concerning median purity, distribution of purity ( Figure 2 ) and recovery of CD34 + cells. Following the first separation step total cell numbers were reduced by approximately 2 log. Thus, one might expect that smaller columns adapted for lower cell numbers may be more suitable for the second step by minimizing nonspecifically bound cells. 11 However, in our experience, the VMACS (small columns) was not superior to the SMACS (large columns). Thus it seems that the conditions under which the CD34 + cells are eluted may be more important than the size of columns used. In the second SMACS step, columns were washed more vigorously and therefore unbound or nonspecifically bound cells could be removed more thoroughly. When more than 1 × 10 8 cells are obtained after the first separation step, the SMACS-SMACS combination is advantageous and time saving, as only one column is recommended for the second step.
FACS analysis of target cells revealed an effective depletion of T cells in all three methods. They prevented signs of significant GVHD (Ͼ1) in the allogeneic setting, even when haploidentical, three loci mismatched donors were used.
Depletion of B cells was less effective, and in some cases distinct populations up to 12.6% CD19 + cells were detectable. However, it must be taken into consideration that this fraction mainly consists of a CD19/CD34 double positive population. As no EBV-associated lymphoproliferative disease was observed, these B cell precursors probably do not impair the clinical results.
The proliferative capability after separation was measured in the clonogenic progenitor cell assay. In each system, a sufficient recovery of Ͼ50% could be observed. Furthermore, the colony-forming efficacy (CFE) calculated for the SMACS-VMACS system showed no significant difference between the initial fraction and the enriched cells. This indicates that the viability and function of stem cells was not influenced by the separation procedure or by remaining magnetic particles which still cover the target cells. Moreover, excellent clinical results confirm that the removal of residual beads is not necessary.
A well documented problem is the correct enumeration of CD34
+ cells in the starting fraction, especially for low numbers of progenitors, thus compromising an accurate determination of the recovery. In 35 of 100 separations, a recovery of Ͼ100% could be observed. We suppose, that initial CD34 + numbers were underestimated by FACS analysis. In order to achieve more reliable results, we additionally used the Procount system for enumeration of CD34 + cells in 30 separations (SMACS-VMACS). However, no significant difference was seen. Although the exact determination of recovery numbers remains unsatisfactory, trends can be observed: a lower recovery for CellPro-VMACS and a superior recovery of about 90% for VMACS-SMACS and SMACS-SMACS. Moreover, these combinations require only one staining procedure, and cells are clearly defined by a single antibody. These systems were thus deemed superior. However, clogging of columns can cause problems. This may be due to cell clumping, overload of cells or by high viscosity samples. In order to overcome this no more than 3 × 10 11 cells were run through each column. When higher cell numbers were processed, several columns were used. Cell numbers up to 10 11 have been treated in this way. Despite filtration procedures, DNase treatment and the use of EDTA buffer, cell clumping could not be prevented in some cases, resulting in a lower recovery.
The recently developed automatic separation device (Clinimacs; Miltenyi Biotec) is also based on the MACS technique. In this system, a multi-step procedure is performed on a single XS + column. McNiece et al 15 found a median purity of 95.5% CD34
+ and a median recovery of 78% when processing leukapheresis products from normal donors. In our laboratory, the Clinimacs device has been used for processing of over 100 samples. A median purity of 97% and a median recovery of 71% with 0.04% contaminating T cells was observed. 16 Thus, purity and depletion of T cells was very similar in all MACS devices. As an advantage, the Clinimacs is automated and time-saving. On the other hand, the two step MACS combinations seem to offer a superior recovery (Ͼ90% vs 70%), and can be better adjusted to the cell numbers to be processed, which might be of importance especially in pediatric patients. Furthermore, costs are less (SMACS and VMACS columns are considerably cheaper than Clinimacs tubing sets) and no expensive equipment is necessary.
In the allogeneic setting T cell depletion is essential in HLA-mismatched donors. Several successful techniques have been developed for this purpose. However, clinical results showed an increased rate of rejection and relapse in T cell depleted bone marrow transplants. 17 This might be due to the relatively low number of infused CD34 + cells. Several authors have thus suggested transplants of CD34 + cell megadoses in order to overcome this problem. 8, 18, 19 We have shown that a rapid and sustained engraftment without GVHD in children is possible when 10 × 10 6 CD34 + cells/kg body weight or more are given, even in the case of haploidentical, three loci mismatched donors. 19, 20 The two-step MACS combinations in particular have yielded high numbers of CD34 + cells without exceeding the critical T cell threshold of 2.5 × 10 4 cells/kg. In the autologous setting effective tumor cell purging is of great interest. A purity of 99% CD34
+ cells in combination with a 2-3 log reduction of the total cell number theoretically results in a tumor cell depletion of at least 3-4 log. 13 Thirty-four patients suffering from neuroblastoma and lymphoma have been successfully transplanted to date, with a median of 3.7 × 10 6 /kg body weight progenitors, obtained by these methods. Since no tumor-specific antibody is required, this procedure can be used in all CD34 negative malignancies. However, further investigations are required to evaluate the purging efficacy by detection of contaminating tumor cells.
In conclusion, particularly the two step MACS systems are clinical scale procedures, resulting in high levels of purity and recovery of CD34 + progenitors, even when faced with low initial CD34 + numbers. Thus it is possible to yield large numbers of progenitors with low T cell content and with low levels of contamination by tumor cells. Encouraging clinical results have already been achieved both in autologous and allogeneic transplantation in pediatric patients.
